Kymera Therapeutics (NASDAQ:KYMR) Earns Outperform Rating from Oppenheimer

Kymera Therapeutics (NASDAQ:KYMR)‘s stock had its “outperform” rating restated by Oppenheimer in a research report issued on Wednesday, Benzinga reports. They presently have a $52.00 price target on the stock. Oppenheimer’s price objective suggests a potential upside of 43.41% from the stock’s current price.

Several other equities research analysts have also issued reports on KYMR. B. Riley raised their price target on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of Kymera Therapeutics in a research note on Monday, June 17th. Seven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $42.09.

Kymera Therapeutics Trading Down 8.1 %

KYMR stock traded down $3.18 during trading on Wednesday, hitting $36.26. The company had a trading volume of 417,821 shares, compared to its average volume of 673,502. The stock has a market cap of $2.22 billion, a PE ratio of -14.25 and a beta of 2.22. Kymera Therapeutics has a one year low of $9.60 and a one year high of $45.31. The business has a 50-day moving average of $33.79 and a 200-day moving average of $34.62.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. The company had revenue of $10.30 million for the quarter, compared to the consensus estimate of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.70) EPS. Research analysts forecast that Kymera Therapeutics will post -2.86 EPS for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Joanna Horobin sold 8,500 shares of the firm’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $32.99, for a total value of $280,415.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Kymera Therapeutics news, Director Joanna Horobin sold 8,500 shares of the firm’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $32.99, for a total value of $280,415.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce Booth sold 16,740 shares of Kymera Therapeutics stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total transaction of $593,433.00. Following the sale, the director now directly owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The disclosure for this sale can be found here. Insiders sold a total of 479,200 shares of company stock valued at $18,219,660 in the last three months. Company insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of KYMR. GSA Capital Partners LLP boosted its stake in Kymera Therapeutics by 141.2% during the third quarter. GSA Capital Partners LLP now owns 51,088 shares of the company’s stock worth $710,000 after acquiring an additional 29,904 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Kymera Therapeutics by 4.9% in the third quarter. Vanguard Group Inc. now owns 3,925,213 shares of the company’s stock worth $54,560,000 after buying an additional 182,125 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Kymera Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock worth $187,000 after buying an additional 1,866 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Kymera Therapeutics in the fourth quarter worth approximately $473,000. Finally, Clear Harbor Asset Management LLC bought a new position in shares of Kymera Therapeutics in the fourth quarter worth approximately $255,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.